SCHEMBL7920495

SCHEMBL7920495

CN(Cc1ccccc1)[C@@H](Cc1ccc2ccccc2c1)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.50
MC4R P32245 2/20 0.48
MC5R P33032 2/20 0.48
MC3R P41968 2/20 0.48
GHSR Q92847 2/20 0.48
HTR2A P28223 2/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
FCER2 P06734 2/20 0.45
MAOB P27338 1/20 0.45
MMP9 P14780 2/20 0.44
MMP8 P22894 1/20 0.44
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
PPARD Q03181 1/20 0.43
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
OPRM1 P35372 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL900942 0.86 ADRA2B (0.54) HTR2AALDH1A1HPGDADRA2BADRA2C
SCHEMBL18375655 0.82 OPRK1 (0.47) ACHEHTR2AHPGDOPRM1ADRA2B
SCHEMBL20362254 0.82 OPRK1 (0.47) ACHEHTR2AHPGDOPRM1ADRA2B
Trifluoroacetic Acid SCHEMBL13733639 0.80 ADRA2B (0.47) HTR2AALDH1A1HPGDADRA2BADRA2C
SCHEMBL3006308 0.80 GHSR (0.51) ACHEMC4RMC5RMC3RGHSR
SCHEMBL17161709 0.77 NPC1 (0.46) HTR2AALDH1A1HPGDADRA2BADRA2C
SCHEMBL7466902 0.77 NPC1 (0.46) HTR2AALDH1A1HPGDADRA2BADRA2C
SCHEMBL17559642 0.77 NPC1 (0.46) HTR2AALDH1A1HPGDADRA2BADRA2C
SCHEMBL5552668 0.76 MC4R (0.63) ACHEMC4RMC5RMC3RGHSR
SCHEMBL7920491 0.76 MC4R (0.63) ACHEMC4RMC5RMC3RGHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10729677-B2 Method for preventing and/or treating chronic traumatic encephalopathy-I EUSTRALIS PHARMACEUTICAL LIMITED (TRADING AS PRESSURA NEURO) (AU) 2020-08-04 US disclosed
US-20160143881-A1 METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I EUSTRALIS PHARMACETICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) 2016-05-26 US disclosed
EP-1107744-A2 USE OF SUBSTANCE P ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA AND USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME Novartis AG (CH) 2001-06-20 EP disclosed
WO-2000010545-A2 USE OF SUBSTANCE P ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND/OR FIBROMYALGIA AND USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME NOVARTIS AG (CH) 2000-03-02 WO disclosed